A phase 1a/1b trial in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma to determine the safety profile, pharmacology, and maximum tolerated dose of ST-001, a Fenretinide Phospholipid suspension (12.5 mg/mL) for IV infusion

Disease:

T-cell Lymphoma, Cutaneous/Peripheral T-Cell Lymphoma, Peripheral T-cell Lymphoma, Peripheral T-Cell Lymphoma, Not Classified, Primary Cutaneous T-cell Lymphoma, Cutaneous T-Cell Lymphoma, Unspecified, Cutaneous T-cell Lymphoma, Follicular T-Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Sézary's Disease, Mycosis Fungoides

Study phase:

Phase I

Physician name:

Auris Huen

Department:

Dermatology

For general questions about clinical trials:

1-844-994-3163